Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Matrix metalloproteinase pharmacogenomics in non-small-cell lung carcinoma.

Pharmacogenomics - 1 Apr 2011

Chetty Chandramu, Rao Jasti S, Lakka Sajani S

Abstract excerpt

Non-small-cell lung carcinoma demonstrated considerable variability in its chemoresponse. However, the prospect of individualized medicine holds high hopes for improving patient survival. The study of tumor and patient genetic profiles, relative to drug-related genes, may offer new opportunities...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Pharmacological
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Genetic Association Studies

Share to Lung Neoplasms

Share to Matrix Metalloproteinases

Share to Pharmacogenetics

Source

Identifiers

PMID: 21521025
DOI: 10.2217/pgs.10.207

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-21521025-2026-09-04.1. Manifest publication-graph-cohort-2026-09-04.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Matrix metalloproteinase pharmacogenomics in non-small-cell lung carcinoma.PMID 21521025Read ↗

Single nucleotide polymorphisms in matrix metalloproteinase genes and lung cancer chemotherapy response and prognosis.Semantic proximity Read ↗

Genetic variants in matrix metalloproteinase genes as disposition factors for ovarian cancer risk, survival, and clinical outcome.Semantic proximity Read ↗

The use of predictive or prognostic genetic biomarkers in endometrial and other hormone-related cancers: justification for extensive candidate gene single nucleotide polymorphism studies of the matrix metalloproteinase family and their inhibitors.Semantic proximity Read ↗

Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck.Semantic proximity Read ↗

Matrix Metalloproteinases Polymorphisms as Prognostic Biomarkers in Malignant Pleural Mesothelioma.Semantic proximity Read ↗

Identification of MMP1 as a potential gene conferring erlotinib resistance in non-small cell lung cancer based on bioinformatics analyses.Semantic proximity Read ↗

The relationship of metalloproteinase gene polymorphisms and lung cancer.Semantic proximity Read ↗

Clinical Significance of Matrix Metalloproteinase-7 and Ets-1 Gene Expression in Patients with Lung CancerSemantic proximity Read ↗

Matrix metalloproteinase 2 polymorphisms and expression in lung cancer: a meta-analysis.Semantic proximity Read ↗

Matrix Metalloproteinase-19 Promotes Metastatic Behavior <i>In Vitro</i> and is Associated with Increased Mortality in Non–Small Cell Lung CancerSemantic proximity Read ↗

Matrix metalloproteinase-2 polymorphisms and clinical outcome of Chinese patients with nonsmall cell lung cancer treated with first-line, platinum-based chemotherapy.Semantic proximity Read ↗

Polymorphism +17 C/G in matrix metalloprotease MMP8 decreases lung cancer risk.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.